Gateway Investment Advisers LLC Has $68.11 Million Holdings in Celgene Corporation (CELG)

Gateway Investment Advisers LLC raised its position in shares of Celgene Corporation (NASDAQ:CELG) by 7.4% in the 2nd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 524,439 shares of the biopharmaceutical company’s stock after buying an additional 36,252 shares during the quarter. Gateway Investment Advisers LLC owned about 0.07% of Celgene Corporation worth $68,109,000 at the end of the most recent reporting period.

Several other hedge funds have also recently added to or reduced their stakes in the business. Sowell Financial Services LLC lifted its position in shares of Celgene Corporation by 0.5% during the first quarter. Sowell Financial Services LLC now owns 2,454 shares of the biopharmaceutical company’s stock valued at $289,000 after buying an additional 13 shares during the last quarter. South Texas Money Management Ltd. lifted its position in shares of Celgene Corporation by 0.6% during the first quarter. South Texas Money Management Ltd. now owns 2,453 shares of the biopharmaceutical company’s stock valued at $305,000 after buying an additional 15 shares during the last quarter. Flagship Harbor Advisors LLC lifted its position in shares of Celgene Corporation by 0.9% during the first quarter. Flagship Harbor Advisors LLC now owns 2,054 shares of the biopharmaceutical company’s stock valued at $253,000 after buying an additional 18 shares during the last quarter. Keel Point LLC lifted its position in shares of Celgene Corporation by 0.9% during the first quarter. Keel Point LLC now owns 3,103 shares of the biopharmaceutical company’s stock valued at $386,000 after buying an additional 28 shares during the last quarter. Finally, Steinberg Global Asset Management lifted its position in shares of Celgene Corporation by 0.6% during the first quarter. Steinberg Global Asset Management now owns 6,594 shares of the biopharmaceutical company’s stock valued at $820,000 after buying an additional 39 shares during the last quarter. 79.33% of the stock is owned by institutional investors and hedge funds.

TRADEMARK VIOLATION WARNING: This report was posted by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are accessing this report on another domain, it was illegally stolen and reposted in violation of United States and international copyright & trademark law. The legal version of this report can be viewed at https://ledgergazette.com/2017/09/23/gateway-investment-advisers-llc-has-68-11-million-holdings-in-celgene-corporation-celg.html.

In other Celgene Corporation news, Director Gilla Kaplan sold 9,250 shares of the company’s stock in a transaction dated Tuesday, September 12th. The stock was sold at an average price of $141.56, for a total transaction of $1,309,430.00. Following the completion of the sale, the director now directly owns 85,551 shares in the company, valued at $12,110,599.56. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Ernest Mario sold 18,506 shares of the company’s stock in a transaction dated Thursday, August 10th. The stock was sold at an average price of $130.52, for a total value of $2,415,403.12. Following the sale, the director now owns 69,424 shares of the company’s stock, valued at $9,061,220.48. The disclosure for this sale can be found here. Insiders have sold 63,006 shares of company stock worth $8,490,806 over the last quarter. 0.95% of the stock is currently owned by company insiders.

Shares of Celgene Corporation (NASDAQ CELG) traded up 0.08% during mid-day trading on Friday, hitting $143.89. The company’s stock had a trading volume of 3,549,466 shares. The company has a market cap of $112.57 billion, a PE ratio of 44.56 and a beta of 1.89. Celgene Corporation has a 12-month low of $96.93 and a 12-month high of $144.19. The stock has a 50-day moving average of $135.45 and a 200-day moving average of $127.81.

Celgene Corporation (NASDAQ:CELG) last released its earnings results on Thursday, July 27th. The biopharmaceutical company reported $1.82 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $1.61 by $0.21. Celgene Corporation had a return on equity of 68.51% and a net margin of 21.35%. The firm had revenue of $3.27 billion for the quarter, compared to the consensus estimate of $3.23 billion. During the same period in the prior year, the business posted $1.44 earnings per share. The firm’s revenue for the quarter was up 18.7% compared to the same quarter last year. On average, equities research analysts forecast that Celgene Corporation will post $7.32 EPS for the current year.

Several research firms have recently issued reports on CELG. BTIG Research downgraded shares of Celgene Corporation from a “buy” rating to a “neutral” rating and upped their price objective for the company from $96.93 to $131.70 in a report on Friday, June 30th. Leerink Swann restated an “outperform” rating and set a $160.00 price objective (up previously from $150.00) on shares of Celgene Corporation in a report on Friday, July 28th. Argus upgraded shares of Celgene Corporation from a “hold” rating to a “buy” rating and upped their price objective for the company from $96.93 to $160.00 in a report on Monday, July 31st. Credit Suisse Group set a $148.00 price objective on shares of Celgene Corporation and gave the company a “buy” rating in a report on Thursday, July 6th. Finally, Cann restated a “buy” rating on shares of Celgene Corporation in a report on Wednesday, June 7th. One investment analyst has rated the stock with a sell rating, seven have assigned a hold rating, twenty-one have issued a buy rating and one has issued a strong buy rating to the company. The company presently has an average rating of “Buy” and a consensus target price of $149.34.

Celgene Corporation Company Profile

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

Want to see what other hedge funds are holding CELG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celgene Corporation (NASDAQ:CELG).

Institutional Ownership by Quarter for Celgene Corporation (NASDAQ:CELG)

Receive News & Ratings for Celgene Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply